News

Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.

Martina Porter, MD, highlights phase 3 data showing povorcitinib boosts hidradenitis suppurativa responses by week 3 and sustains gains to 54 weeks in refractory patients.

See how precision biologics—dupilumab, IL-13/IL-31 blockers, JAK inhibitors, and omalizumab—change treatment for atopic dermatitis and chronic spontaneous urticaria.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Eileen Cheever, PA, discussed how understanding immunologic pathways can strengthen patient counseling and treatment confidence in dermatology.

In this episode, Miles Harrison and Brian Pilcher, PhD, explain investigational ECM injectables that aim to restore tissue scaffold for wound healing and address post–GLP-1 skin quality changes beyond fillers.

Leon Kircik, MD, discusses the allosteric binding mechanism and safety profile data of zasocitinib in hard-to-treat psoriasis presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

FDA clears Labcorp’s NGS tissue test to quickly spot BRAF V600E/K melanoma, guiding targeted BRAF/MEK therapy selection in days.

Sonelokimab met the primary end point in phase 3 IZAR-1, with 42.1% of biologic-naive patients achieving ACR50 at week 16.

HS microbiome studies fuel probiotic hype, but a new review finds evidence too thin for routine use and highlights key research gaps.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Does facial massage with a gua sha improve skin or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Jerry Shapiro, MD, discusses rapid hair growth and safety findings for oral minoxidil, VDPHL01, in female pattern hair loss.

Isoclear regimen combines topical isotretinoin with stage-specific ingredients from active treatment through long-term maintenance

New oral TYK2 inhibitor shows rapid PASI 75/90 skin clearance in phase 2 plaque psoriasis study, with encouraging safety.

The accelerated FDA approval, based on Replimune's phase 2 IGNYTE trial data, gives clinicians a new second-line option for adults with advanced melanoma progressing after anti-PD-1 therapy.

Obesity may blunt biologic psoriasis gains, according to a 4,200‑patient meta‑analysis showing lower PASI responses, but weight alone shouldn’t drive drug choice.

Leon Kircik, MD, outlines phase 3 zasocitinib data on palmoplantar psoriasis skin clearance presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Aaron Farberg, MD, discusses how localized isotretinoin delivery may affect treatment burden, tolerability, and adherence.

Absci's ABS-201 posts early phase 1 safety and long half-life, while new data show prolactin-receptor blockade may revive hair growth in AGA.

The European Commission greenlights upadacitinib for severe alopecia areata, with phase 3 data showing rapid scalp, brow and lash regrowth; US decision still pending.

Conexeu is advancing its ECM-regenerating tissue tech, targeting wound care via FDA 510(k) and eyeing aesthetics, reconstruction, and beyond.

Karen McGuire, PhD, CEO and co-founder of BioMendics, explains what fast track status means for the investigational treatment and details the drug's mechanism of action in EBS.

This review of the latest dermatological studies includes insights on fibromyalgia in rosacea patients, isotretinoin use and suicidality in adolescents, patient-centered teledermatology, and more.

Leon Kircik, MD, discusses zasocitinib scalp psoriasis clearance rates from the LATITUDE 1 and 2 trials presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.

AAD guidelines strongly recommend roflumilast, ruxolitinib, and tapinarof, expanding steroid-sparing options for pediatric atopic dermatitis.

Explore the top dermatology conferences and meetings happening this month and let us know which ones you'll be attending!

FDA reviews phase 3 results and expanded BOTOX Cosmetic use for masseter prominence and nonsurgical jawline contouring, potentially becoming the first neurotoxin approved in the US for this indication.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.